Search

Your search keyword '"PERRY, Chava"' showing total 427 results
Start Over Author "PERRY, Chava"
427 results on '"PERRY, Chava"'

53. Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells

Author

Shorer Arbel, Yamit, primary, Katz, Ben-Zion, additional, Gabizon, Ronen, additional, Shraga, Amit, additional, Bronstein, Yotam, additional, Kamdjou, Talia, additional, Globerson Levin, Anat, additional, Perry, Chava, additional, Avivi, Irit, additional, London, Nir, additional, and Herishanu, Yair, additional

Published
2021
Full Text
View/download PDF

58. Toxicity and Efficacy of CAR-T in Patients with DLBCL Above the Age of 70 Years Compare to Younger Patients – a Matched Control Multi-Center Cohort Study

Author

Ram, Ron, primary, Grisariu, Sigal, additional, Shargian, Liat, additional, Amit, Odelia, additional, Bar-On, Yael, additional, Stepansky, Polina, additional, Yeshurun, Moshe, additional, Avni, Batia, additional, Hagin, David, additional, Perry, Chava, additional, Gurion, Ronit, additional, Sarid, Nadav, additional, Herishanu, Yair, additional, Gold, Ronit, additional, Kay, Sigi, additional, and Avivi, Irit, additional

Published
2021
Full Text
View/download PDF

66. Anti-CD20-Mediated B Cell Depletion Is Associated with Reduced Osteoclastogenic Signals and Bone Mass Preservation: Clinical Observation in Patients with Follicular Lymphoma Supplemented By Animal Studies in a Murine Model

Author

Kolomansky, Albert, primary, Kay, Irit, additional, Ben-Califa, Nathalie, additional, Gorodov, Anton, additional, Awida, Zamzam, additional, Sadovnic, Ofer, additional, Ibrahim, Maria, additional, Liron, Tamar, additional, Hiram-Bab, Sahar, additional, Oster, Howard S., additional, Sarid, Nadav, additional, Perry, Chava, additional, Gabet, Yankel, additional, Mittelman, Moshe, additional, and Neumann, Drorit, additional

Published
2020
Full Text
View/download PDF

69. Anti-CD20-Mediated B Cell Depletion Is Associated With Bone Preservation in Lymphoma Patients and Bone Mass Increase in Mice

Author

Kolomansky, Albert, primary, Kaye, Irit, additional, Ben-Califa, Nathalie, additional, Gorodov, Anton, additional, Awida, Zamzam, additional, Sadovnic, Ofer, additional, Ibrahim, Maria, additional, Liron, Tamar, additional, Hiram-Bab, Sahar, additional, Oster, Howard S., additional, Sarid, Nadav, additional, Perry, Chava, additional, Gabet, Yankel, additional, Mittelman, Moshe, additional, and Neumann, Drorit, additional

Published
2020
Full Text
View/download PDF

70. Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience

Author

Segman, Yafit, primary, Ribakovsky, Elena, additional, Avigdor, Abraham, additional, Goldhecht, Yair, additional, Vainstein, Vladimir, additional, Goldschmidt, Neta, additional, Harlev, Shimrit, additional, Horwitz, Netanel, additional, Gutwein, Odit, additional, Gurion, Ronit, additional, Itchaki, Gilad, additional, Abadi, Uri, additional, Nemets, Anatoly, additional, Sofer, Orit, additional, Zektser, Miri, additional, Tadmor, Tamar, additional, Dally, Nagib, additional, Filanovsky, Kalman, additional, Leiba, Merav, additional, Sarid, Nadav, additional, Benyamini, Noam, additional, Herishanu, Yair, additional, Ram, Ron, additional, Perry, Chava, additional, and Avivi, Irit, additional

Published
2020
Full Text
View/download PDF

73. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group

Author

Herishanu, Yair, primary, Shaulov, Adir, additional, Fineman, Riva, additional, Bašić‐Kinda, Sandra, additional, Aviv, Ariel, additional, Wasik‐Szczepanek, Ewa, additional, Jaksic, Ozren, additional, Zdrenghea, Mihnea, additional, Greenbaum, Uri, additional, Mandac, Inga, additional, Simkovic, Martin, additional, Morawska, Marta, additional, Benjamini, Ohad, additional, Spacek, Martin, additional, Nemets, Anatoly, additional, Bairey, Osnat, additional, Trentin, Livio, additional, Ruchlemer, Rosa, additional, Laurenti, Luca, additional, Stanca Ciocan, Oana, additional, Doubek, Michael, additional, Shvidel, Lev, additional, Dali, Nagib, additional, Mirás, Fátima, additional, De Meûter, Anne, additional, Dimou, Maria, additional, Mauro, Francesca R., additional, Coscia, Marta, additional, Bumbea, Horia, additional, Szász, Róbert, additional, Tadmor, Tamar, additional, Gutwein, Odit, additional, Gentile, Massimo, additional, Scarfò, Lydia, additional, Tedeschi, Alessandra, additional, Sportoletti, Paolo, additional, Gimeno Vázquez, Eva, additional, Marquet, Juan, additional, Assouline, Sarit, additional, Papaioannou, Maria, additional, Braester, Andrei, additional, Levato, Luciano, additional, Gregor, Michael, additional, Rigolin, Gian M., additional, Loscertales, Javier, additional, Medina Perez, Angeles, additional, Nijziel, Marten R., additional, Popov, Viola M., additional, Collado, Rosa, additional, Slavutsky, Irma, additional, Itchaki, Gilad, additional, Ringelstein, Shimrit, additional, Goldschmidt, Neta, additional, Perry, Chava, additional, Levi, Shai, additional, Polliack, Aaron, additional, and Ghia, Paolo, additional

Published
2020
Full Text
View/download PDF

76. [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies.

Author

Cohen, Dan, Luttwak, Efrat, Beyar-Katz, Ofrat, Hazut Krauthammer, Shir, Bar-On, Yael, Amit, Odelia, Gold, Ronit, Perry, Chava, Avivi, Irit, Ram, Ron, and Even-Sapir, Einat

Subjects
PROGRESSION-free survival, DIFFUSE large B-cell lymphomas, B cell lymphoma, PATIENT selection, CELLULAR therapy, CHIMERIC antigen receptors, STATISTICS, MULTIVARIATE analysis, CELL receptors, CANCER patients, PRE-tests & post-tests, TREATMENT effectiveness, RADIOPHARMACEUTICALS, POSITRON emission tomography, SURVIVAL analysis (Biometry), DESCRIPTIVE statistics, DEOXY sugars, COMPUTED tomography, T cells
Abstract

Purpose: The introduction of CD19-specific chimeric antigen receptor T-cell therapy (CAR-T) for treatment of relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) gives hope to patients with otherwise dismal prognosis. Therapy outcomes, however, depend upon selection of patients and accurate early identification of non-responders. Patients treated with CAR-T usually undergo [18F]FDG PET-CT at time of decision (TD), time of CAR-T transfusion (TT), 1 month (M1), and 3 months (M3) post-therapy. The purpose of the current study was to identify the specific parameters that should be addressed when reporting PET-CT studies in the clinical setting of CAR-T therapy. Methods: A total of 138 PET-CT scans (30 TD, 42 TT, 44 M1, 22 M3) of 48 patients treated with CAR-T were included. SUVmax, TMTV, and TLG were calculated in all scans. Response was assessed using the Deauville scale and ΔSUVmax method. Overall survival (OS) was the primary endpoint. Median follow-up was 12.8 (IQR 6.4–16.0) months from CAR-T infusion. Results: In a univariate analysis, TD-SUVmax > 17.1 and TT-SUVmax > 12.1 were associated with shorter OS (Pv < 0.05). In a multivariate analysis, three factors were significantly associated with shorter OS: TD-SUVmax > 17.1 (HR 10.3; Pv < 0.01), LDH > 450 U/l (HR 7.7; Pv < 0.01), and ECOG score > 1 (HR 5.5; Pv = 0.04). Data from TD and TT PET-CT scans were not predictive of toxicity. On M1-PET-CT, patients with a Deauville score > 3 had significantly shorter OS (median 7.9 months, versus not reached, Pv < 0.01). ΔSUVmax ≤ 66% on M1-PET-CT predicted shorter OS when M1-SUVmax was compared to TD-SUVmax (Pv = 0.02) but not to TT-SUVmax (Pv = 0.38). Conclusion: Pre-treatment SUVmax may guide patient selection for CAR-T therapy. On M1-PET-CT, Deauville score and ΔSUVmax from TD may identify early therapy failure. These parameters are easy to obtain and should be included in the PET-CT report. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

77. Characteristics and recognition of early infections in patients treated with commercial anti‐CD19 CAR‐T cells.

Author

Beyar‐Katz, Ofrat, Kikozashvili, Nino, Bar On, Yael, Amit, Odelia, Perry, Chava, Avivi, Irit, Gold, Ronit, Herishanu, Yair, Benyamini, Noam, Duek, Adrian, Ben‐Ami, Ronen, Shasha, David, and Ram, Ron

Subjects
DIFFUSE large B-cell lymphomas, INFECTION, CYTOKINE release syndrome, BACTERIAL diseases, CHIMERIC antigen receptors, OLDER patients
Abstract

The characteristics of infections following chimeric antigen receptor T (CAR‐T) cells targeting CD19 in real‐word population are obscure. We analyzed infections' characteristics in the first month among consecutive patients with diffuse large B‐cell lymphoma (DLBCL) (n = 60, median age, 69.3 years), treated with commercial CAR‐T cells. ECOG performance status (PS) was 2‐3 in most patients (58%). Infections were observed in 45% of patients (16, 27%, bacterial infections, and 14, 23%, viral infections). Bacterial infection included clinically documented infection in 7 (Pneumonia, n = 5; periodontal infection, n = 1; and cellulitis, n = 1) and microbiology documented infection (MDI) in 9 patients (Gram‐negative rod, n = 5; Gram‐positive cocci, n = 3, bacteremia; polymicrobial, n = 1). The most common viral infection was cytomegalovirus (CMV) reactivation (n = 10, 17%) leading to initiation of anti‐CMV treatment in 6 (60%) among these patients. None had CMV disease. In univariate analysis, immune effector cell‐associated neurotoxicity syndrome (ICANS) was associated with higher incidence of bacterial infection (OR=4.5, P =.018), while there was a trend for lower incidence of bacterial infections in patients with chemosensitive disease to bridging therapy (OR=0.375, P =.074). Age or PS was not associated with increased risk of bacterial infection. Increase in C‐reactive protein (CRP) prior to fever onset was associated with microbiologically documented infections. We conclude that infections are common in the first month following CAR‐T‐cell administration, however, were not increased in elderly patients or those presenting with poorer PS. Increase in CRP prior to fever onset could support infection over cytokine release syndrome. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

81. Continuing dilemmas in the management of lymphoma during pregnancy: review of a 10-point case-based questionnaire

Author

Herishanu Yair, Joffe Erel, Sarid Nadav, Lishner Michael, Avivi Irit, Amit Odelia, and Perry Chava

Subjects
medicine.medical_specialty, Pediatrics, medicine.medical_treatment, Follicular lymphoma, Gestational Age, Vinblastine, 03 medical and health sciences, Birth Intervals, 0302 clinical medicine, Pregnancy, Chemoimmunotherapy, Surveys and Questionnaires, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Israel, Practice Patterns, Physicians', Lymphoma, Follicular, Gynecology, Chemotherapy, business.industry, Retrospective cohort study, Hematology, General Medicine, medicine.disease, Hodgkin Disease, Magnetic Resonance Imaging, Lymphoma, Radiation therapy, Review Literature as Topic, Methotrexate, Oncology, 030220 oncology & carcinogenesis, Female, Steroids, Surgery, Lymphoma, Large B-Cell, Diffuse, Pregnancy Trimesters, business, Pregnancy Complications, Neoplastic, 030215 immunology, medicine.drug
Abstract

Due to the rarity of lymphoma during pregnancy, management guidelines are based upon evidence from retrospective studies and case reports. Here, we review the major dilemmas in the field and examine the approach of hemato-oncologists in Israel to the management of lymphoma in pregnancy. We performed a literature search on the PubMed database using keywords for all papers on the subject from 1990−2014. The papers were reviewed by an expert panel who devised a questionnaire covering the main dilemmas. Sixty questionnaires were sent out. Non-contrast magnetic resonance imaging was the staging modality of choice. Chemoimmunotherapy was considered relatively safe beyond the first trimester except methotrexate (completed postpartum). Steroids or vinblastine were suggested by most as a reasonable ‘bridging therapy’ until the second trimester in Hodgkin lymphoma. The dosage of chemoimmunotherapy employed during pregnancy remained debatable; the majority recommended dosage according to actual pregnancy weight. Optimal timing for delivery was considered by most to be >35 weeks. Regarding approach to next pregnancy for patients in complete remission from diffuse large B-cell lymphoma, 69 % advised waiting 2 years but the majority advised 6−12 months for follicular lymphoma. Despite consensus regarding the safety of chemotherapy post first trimester, optimal dosage, central nervous system therapy, timing of delivery and approach to future pregnancies remain controversial, indicating a need for further collaborative research in this field.

Published
2016

82. Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Author

Segman, Yafit, primary, Ribakovsky, Elena, additional, Avigdor, Abraham, additional, Vainstein, Vladimir, additional, Goldschmidt, Neta, additional, Harlev, Shimrit Ringelstein, additional, Gutwein, Odit, additional, Abadi, Uri, additional, Nemets, Anatoly, additional, Sofer, Orit, additional, Dally, Najib, additional, Filanovsky, Kalman, additional, Leiba, Merav, additional, Sarid, Nadav, additional, Benyamini, Noam, additional, Herishanu, Yair, additional, Ram, Ron, additional, Perry, Chava, additional, and Avivi, Irit, additional

Published
2019
Full Text
View/download PDF

83. Is the Achievement of Pre-Autologous Transplant CR Necessary Indeed in Refractory/ Relapsed DLBCL Patients? a Retrospective Multicenter Study

Author

Shargian-Alon, Liat, primary, Bernstine, Hanna, additional, Perets, Galit, additional, Gurion, Ronit, additional, Gafter-Gvili, Anat, additional, Pasvolsky, Oren, additional, Navon Sela, Michal, additional, Perry, Chava, additional, Avivi, Irit, additional, Amit, Odelia, additional, Raanani, Pia, additional, Ram, Ron, additional, and Yeshurun, Moshe, additional

Published
2019
Full Text
View/download PDF

85. Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study

Author

Perry, Chava, primary, Ben Barouch, Sharon, additional, Goldschmidt, Neta, additional, Sarid, Nadav, additional, Herishanu, Yair, additional, Shvidel, Lev, additional, Bairey, Osnat, additional, Lavi, Noa, additional, Horowitz, Netanel, additional, Avigdor, Avraham, additional, Lebel, Eyal, additional, Sofer, Orit, additional, Ram, Ron, additional, and Avivi, Irit, additional

Published
2019
Full Text
View/download PDF

88. Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma.

Author

Herishanu, Yair, Levi, Shai, Kamdjou, Talia, Bornstein, Yotam, Ram, Ron, Benyamini, Noam, Varon, David, Avivi, Irit, and Perry, Chava

Subjects
AUTOIMMUNE hemolytic anemia, LYMPHOCYTIC leukemia, CHRONIC leukemia, IDIOPATHIC thrombocytopenic purpura
Abstract

Keywords: obinutuzumab; AIHA; ITP; CLL EN obinutuzumab AIHA ITP CLL e1 e4 4 12/21/20 20210101 NES 210101 Obinutuzumab is a type II, glycoengineered, humanized anti-CD20 monoclonal antibody, with enhanced direct cell death and antibody-dependent cell-mediated cytotoxicity.1 Obinutuzumab is FDA-approved for chronic lymphocytic leukaemia (CLL) in combination with chlorambucil, ibrutinib or venetoclax as a first-line treatment.2-4 Similar to rituximab, obinutuzumab induces B-cell depletion and reduced antibody production, granting it the potential to effectively treat antibody-mediated autoimmune phenomena. We report here a retrospective analysis of eight patients with CLL/small lymphocytic lymphoma (SLL) who were treated with single-agent obinutuzumab for autoimmune haemolytic anaemia (AIHA) or immune thrombocytopenia (ITP), from September 2018 to March 2020. Among our patients, the results achieved with obinutuzumab were especially impressive in a patient with ITP, resistant to multiple therapies, including splenectomy and rituximab, who rapidly responded to obinutuzumab. A prospective randomized trial comparing the efficacy of obinutuzumab and rituximab in the treatment of AIHA/ITP in patients with CLL/SLL, as well as the optimal duration of treatment (e.g. short-term obinutuzumab), is warranted. [Extracted from the article]

Published
2021
Full Text
View/download PDF

90. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.

Author

Shimony, Shai, Horowitz, Netanel, Ribakovsky, Elena, Rozovski, Uri, Avigdor, Abraham, Zloto, Keren, Berger, Tamar, Avivi, Irit, Perry, Chava, Abadi, Uri, Raanani, Pia, Gafter‐Gvili, Anat, Gurion, Ronit, and Gafter-Gvili, Anat

Subjects
CUTANEOUS T-cell lymphoma, T-cell lymphoma, HISTONE deacetylase, ENZYME inhibitors, CANCER treatment, ANTINEOPLASTIC antibiotics, COMPARATIVE studies, DRUG resistance in cancer cells, MEDICAL cooperation, PEPTIDES, PROGNOSIS, REOPERATION, RESEARCH, SKIN diseases, DISEASE relapse, EVALUATION research, TREATMENT effectiveness, KAPLAN-Meier estimator
Abstract

Romidepsin is a class I selective histone deacetylase (HDAC) inhibitor approved by the Food and Drug Administration (FDA) for relapsed/refractory (R/R) cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL), treated with at least one prior systemic therapy. Currently, there is paucity of real-life data on the efficacy and safety of romidepsin in R/R T-cell lymphoma. This national, multicenter study presents real-life data on the efficacy and safety of romidepsin in R/R T-cell lymphoma. Patients diagnosed and treated with romidepsin for R/R CTCL or PTCL between 2013 and 2018 were retrospectively reviewed. Outcomes included overall survival (OS), event-free survival (EFS), overall response rate (ORR), complete response (CR), and adverse events. Fifty-three patients with R/R PTCL (n = 42) or CTCL (n = 11) were included. Among CTCL patients, median OS was not reached, ORR was 25%, and none achieved CR. Among PTCL patients, median OS was 7.1 months, EFS was 1.9 months, ORR rate was 33%, and 12.5% achieved CR. In a univariate analysis, predictors for longer EFS include any response to therapy, number of previous lines, and PTCL subclass (with better results for angioimmunobalstic T-cell lymphoma). In a univariate and multivariate analysis for OS, treatment response was the only factor predicting OS (OR 4.48; CI 95%, 1.57-12.79; P = .005). Most grade 3 and 4 adverse events were hematological (35%). Infections were reported in 34% of patients. This real-life experience with romidepsin confirms the results of the pivotal phase II trials. PTCL subtype and the number of previous lines of therapy have an impact on EFS. In addition, patients who had good response to romidepsin benefited most in terms of both EFS and OS. Efforts should be done to identify those patients. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

94. Treatment and prognosis of stage I follicular lymphoma in the modern era – does PET matter?

Author

Bentur, Ohad S., primary, Gurion, Ronit, additional, Gafter-Gvili, Anat, additional, Gatt, Moshe, additional, Shvidel, Lev, additional, Horowitz, Netanel A., additional, Ram, Ron, additional, Herishanu, Yair, additional, Sarid, Nadav, additional, Paltiel, Ora, additional, Ganzel, Chezi, additional, Kreiniz, Natalia, additional, Dally, Najib, additional, Gutwein, Odit, additional, Raanani, Pia, additional, Avivi, Irit, additional, and Perry, Chava, additional

Published
2017
Full Text
View/download PDF

98. Real-Life Experience of Nivolumab in Heavily Pretreated Relapsed and Refractory Classical Hodgkin Lymphoma

Author

Benjamini, Ohad, primary, Lavie, David, additional, Dann, Eldad J, additional, Perry, Chava, additional, Rouvio, Ory, additional, Shvetz, Olga, additional, Nemets, Anatoly, additional, Perets, Ruth, additional, Saban, Revital, additional, Shimoni, Avichai, additional, Ben-Yehuda, Dina, additional, Nagler, Arnon, additional, and Avigdor, Abraham, additional

Published
2016
Full Text
View/download PDF

100. Wide-range effects of the MALT-1 inhibitor Mi-2 in CLL cells results in apoptosis.

Author

Dezorella, Nili, Ashkenazi, Enosh, Shapiro, Mika, Perry, Chava, Kamdjou, Talia, Katz, Ben-Zion, and Herishanu, Yair

Subjects
FLUDARABINE, MUCOSA-associated lymphoid tissue lymphoma, CELL receptors, B cell receptors
Abstract

The article presents a study on the use of the mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitor in analyzing chronic lymphocytic leukemia (CLL) cells. It notes that studied CLL cells were taken from patients' blood samples. A chart is presented on the Mi-2 apoptosis in CLL cells.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results